Navigation Links
Isis in Medical News

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2009 Financial Results Conference Call

CARLSBAD, Calif., July 23 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Isis Pharmaceuticals' Second Quarter 2009 Financial Results When: Thursday, August 6, 2009 at 8:30 a.m. ET / 5:30 a.m. PT ...

Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in Conjunction with 2009 Annual Meeting of Stockholders

CARLSBAD, Calif., May 19 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Isis Pharmaceuticals to provide a general corporate update in conjunction with the 2009 Annual Meeting of Stockholders. The co...

Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review

NEW ORLEANS and CARLSBAD, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Isis' cardiovascular program review of development and late-stage research candidates, including presentations ...

FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen

Isis to Host Conference Call Today at 8 a.m. EDT CARLSBAD, Calif. and CAMBRIDGE, Mass., April 25 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) and Genzyme Corp. (Nasdaq: GENZ ) announced today that the FDA has provided guidance regarding approval requirements for mip...

Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS

CARLSBAD, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to ISIS 333611 for the treatment of an inherited form of amyotrophic lateral sclerosis (ALS), commonly...

Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes

CARLSBAD, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced that it has added a new diabetes drug targeting the sodium dependent glucose transporter type 2 (SGLT2) to its development pipeline. ISIS 388626, a generation 2.2 antisense drug that...

Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012

- ISIS 301012 given generic name mipomersen sodium - Isis further reduces its 2007 net operating loss guidance to mid to high $20 million range - Isis will host a conference call this morning at 8:00 a.m. E.T. at http://www.isisph...

Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months

- Twelve of Sixteen FH Patients in an Ongoing Open-Label Extension Study Have Been Dosed With ISIS 301012 for Approximately Five Months or More, and Four Have Been Dosed for More Than Six Months - Isis Will Host a Conference Call on Monday, October 8, at 8:00 a.m. E.T. ...

Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis

CARLSBAD, Calif. and ABBOTT PARK, Ill., Jan. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) and Abbott (NYSE: ABT ) announced today that Abbott has completed its purchase of Ibis Biosciences, Inc., an Isis subsidiary, for a closing purchase price of $175 million. In ad...

Grassrootshealth Launches D*action Community Project to Solve Vitamin D Deficiency Crisis

Serving as a model for public health action on vitamin D, GrassrootsHealth, an advocacy organization has launched the D*action Community Project, a consortium of scientists, institutions and individuals committed to solving the worldwide vitamin D deficiency crisis and will hold its first event, ...

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

...CARLSBAD, Calif., Aug. 4 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ), the leader in antisense therapeutics, today ann...eplay of the presentation will be available on the isis Web site within 48 hours and will be archived for ...

Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development

...nd, Canada Validation of LRRK2 as a drug target for treatment of Parkinson's disease using antisense technology Alejandro Lloret, PhD, isis Pharmaceuticals, Inc., Carlsbad, California Optimizing lead series of small molecule inhibitors of LRRK2 to deliver tool compounds and clini...

Vanderbilt researchers pioneer an advanced sepsis detection and management system

...dly, expensive and treatable. At the same time, isis computer scientists were investigating the issue o...gy) Science and Technology Center. When Miller and isis Director Janos Sztipanovits compared notes, they realized that isis had developed computer-modeling tools that could b...

Isis Pharmaceuticals to Present at Jefferies' 3rd Annual Healthcare Conference

...ARLSBAD, Calif., June 11 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ), the leader in antisense therapeutics, today ann...eplay of the presentation will be available on the isis Web site within 48 hours and will be archived for ...

Isis Pharmaceuticals to Present at Needham's 8th Annual Life Sciences Conference

...CARLSBAD, Calif., June 5 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ), the leader in antisense therapeutics, today ann...eplay of the presentation will be available on the isis Web site within 48 hours and will be archived for ...

Isis Pharmaceuticals to Present at Goldman Sachs' 30th Annual Global Healthcare Conference

...CARLSBAD, Calif., June 4 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ), the leader in antisense therapeutics, today ann...eplay of the presentation will be available on the isis Web site within 48 hours and will be archived for ...

Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO

...CARLSBAD, Calif., June 1 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced today that Isis' collaborators present...1 and OGX-427 are antisense drugs co-discovered by isis and OncoGenex (Nasdaq: OGXI ) and...

Isis Reports Strong Financial Results and Highlights for First Quarter of 2009

... CARLSBAD, Calif., May 7 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced its financial results for the qu...marily as a result of the $171.8 million gain that isis recognized from selling its Ibis Biosciences subsi...

Isis Scientist Awarded 2009 Ebert Prize

...ARLSBAD, Calif., April 6 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced today that Lloyd G. Tillman, Ph.D., Executive Director of Pharmaceutical Development of isis has been awarded the American Pharmacists Associat...

Isis Reports Strong Financial Results and Highlights for Fiscal Year 2008

...ARLSBAD, Calif., Feb. 25 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced its 2008 financial results and business highlights. isis exceeded its 2008 financial guidance by ending 200...

Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008

...of the strengthening of the U.S. dollar against the English pound, Labcaire sales increased $795,000 in the second quarter due to shipments of our new isis endoscope cleaning system, endoscope storage cabinet and increased service revenue. In light of the challenging global economic environment, w...

Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference

...CARLSBAD, Calif., Jan. 8 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced that the Company will present at the 2...imited time on the Company's Web site. About isis Pharmaceuticals, Inc. ...

A glass apart

... and Technology Facilities Council's world leading isis neutron source. Research at isis is showing exactly how the calcium is held in the ...lains that it was when the material was studied at isis that the process became clear. "Although variants...

Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology

...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced today that two of the Company's partne...as jointly discovered and is being co-developed by isis and OncoGenex. Lilly presented first-in-human data...h.D., Vice President of Drug Discovery Research at isis Pharmaceuticals. "The encouraging safety profiles ...

Isis to Receive $4.6 Million From Alnylam

...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced today that it will receive $4.6 millio... value of Isis' innovation and the leadership role isis has played in the field of nucleic acid based therapeutics. isis owns or controls more than 1,500 issued patents, t...

Isis Reports Financial Results and Highlights for First Quarter of 2008

...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced its financial results for the qu...successful partnering activities. On a GAAP basis, isis recorded a 2008 loss from operations for the quart...lion in the first quarter of 2007, a 58% decrease. isis remains on track to meet its 2008 guidance for a N...

Isis Reports Financial Results and Highlights for Fiscal year 2007

...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced its 2007 financial results and b...e to its strong financial performance during 2007, isis reduced its 2007 NOL guidance from the mid to high...ivities, which are not part of ongoing operations. isis has regularly reported non-GAAP measures for opera...

QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Cancer Indexes

...the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on March 10, 2008, ISIS Pharmaceuticals (Nasdaq: isis ) will replace Pharmion Corp. (Nasdaq: PHRM ) in the HealthShares(TM) Composite Index. Synta Pharmaceuticals Corp. (Nasdaq: SNTA ) will replace Phar...

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year

...ently in phase 3 clinical trials for high-risk cardiovascular disease patients. Mipomersen, which Genzyme is in the process of licensing from isis Pharmaceuticals Inc., will strengthen an already substantial pipeline. The product will join Mozobil and alemtuzumab at the forefront of a de...

Isis Announces Approximately $2.8 Million in Government Grants and Contracts Awarded to its Ibis Subsidiary to Advance Ibis' Pathogen Identification Technology

...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced today that its majority-owned subsidia...s' homepage at http://www.isispharm.com . ABOUT isis PHARMACEUTICALS, INC. isis is exploiting its expertise in RNA to discover and...

Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy

...Phase II trials are set to begin for survivin ASO, an antisense molecule targeted at solid tumors that Lilly is developing with its partner, isis Pharmaceuticals; a second antisense molecule targeted at solid tumors, eIF-4E ASO, is also set to begin Phase II studies in 2008. The compan...

Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases

...CINITAS, Calif., Nov. 27 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) and Excaliard Pharmaceuticals, Inc. announced to...isense drugs. Excaliard made an upfront payment to isis in the form of equity and paid...

Abt Associates to Lead Major Evaluation of Programs Aimed at Promoting Self-Sufficiency for Disadvantaged Families

... promoting employment and self-sufficiency. Working with Abt Associates on isis will be a cadre of experienced field consultants and staff from the followi...fficiency and economic well-being of low income families with children. The isis team will identify programs and populations for evaluation through a collab...

Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007

...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced that it has received a $1.25 mil...nical trials of iCo-007, a drug licensed to iCo by isis in 2005 for the treatment of various eye diseases,...nnett, Ph.D., Senior Vice President of Research at isis Pharmaceuticals, Inc. "We are enthusiastic about t...

Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.

...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced that it has received clearance u...September 13, 2007. As part of the collaboration, isis is granting to Ortho-McNeil worldwide development ...ercialization rights to two of its diabetes drugs, isis 325568 and...

Isis Acquires Symphony GenIsis

... isis 301012 now under Isis' ownership in preparation fo...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ), today announced its purchase of all of the equi...Prompting this transaction, on September 13, 2007, isis announced its metabolic disease-focused collaborat...

HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... Nasdaq: AXCA Isis Pharmaceuticals Nasdaq: isis Add GPC Biotech AG-Sponsored ADR Nasdaq: GPCB QLT, Inc. .../WA SGEN 606061817.2 ISIS PHARMACEUTICALS INC isis 496697278.7 HealthShares Respiratory/Pulmonary Index Company ...

Molecular Therapy Holds Promise in the Treatment of Amyotrophic Lateral Sclerosis

... Researchers from the University of California, San Diego (UCSD) School of Medicine, the Center for Neurologic Study and isis Pharmaceutical Corporation have created// and tested molecular therapy in animals which they feel will assist in the treatment of amyotrophic lateral ...
Other Tags
(Date:7/9/2014)... bladders of healthy women differ from bacteria in ... to researchers from Loyola University Chicago Stritch School ... 9, 2014, in the American Society for Microbiology,s ... communities may play a role in female urinary ... common, yet poorly understood, condition with symptoms similar ...
(Date:7/9/2014)... Centre (CNIO) have discovered that NANOG, an essential gene ... stratified epitheliathose that form part of the epidermis of ... adult organisms. According to the conclusions of the study, ... factor could also play a role in the formation ... and skin. , The pluripotency factor NANOG is active ...
(Date:7/9/2014)... studying critically ill children with traumatic injuries have ... are likely to develop a hospital-acquired infection. The ... and published online in June in the journal ... efforts that could lead to the clinical implementation ... prevent or reverse immune system damage following critical ...
Breaking Biology News(10 mins):CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
(Date:7/9/2014)... Fox Chase Cancer Center paint a relatively optimistic picture ... cancers that have spread to the chest wall or ... into the skin, regardless of size and whether they ... III and called "locally advanced" tumors, suggesting that ... with poor survival. Locally advanced breast cancers of this ...
(Date:7/9/2014)... release is available in French . ... in 14 year old teens, including brain structure and function, ... accuracy who will go on to develop binge drinking within ... conscientiousness, and other variables such as life events and a ... binge drinking. Whether or not the child had had ...
(Date:7/9/2014)... It may smell of flatulence and have a reputation for ... dosage, hydrogen sulfide is now being being found to offer ... to stroke, heart attacks and dementia. A new compound (AP39), ... the key to future therapies, by targeting delivery of very ... places inside cells. , Scientists in Exeter have already ...
(Date:7/9/2014)... with kidney and heart disease have raised concerns about ... However, in the first study to look closely at ... at the University of Pennsylvania report that older kidney ... and cardiovascular health as very healthy older people who ... ever increasing organ transplant waitlists, the authors of the ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:What drives a child to abuse alcohol? 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
Other Contents